Evaluation of time to onset and outcome of cardiac adverse events associated with nilotinib using post-marketing surveillance

CONCLUSIONS: We focused on CAEs caused by nilotinib as post-marketing AEs. Some cases resulted in serious outcomes. Patients should be monitored for signs of onset of these AEs not only at the start of administration, but for a long period of time.PMID:37598671 | DOI:10.1159/000533325

Source: Oncology - August 20, 2023 Category: Cancer & Oncology Authors: Yuko Kanbayashi Asuka Kojima Haruka Wakabayashi Tadashi Shimizu Mayako Uchida Source Type: research